Impaired IFNγ responsiveness of monocyte-derived lung cells limits immunity to Mycobacterium tuberculosis

This study reveals that a specific subset of monocyte-derived lung cells limits immunity to *Mycobacterium tuberculosis* due to impaired IFNγ signaling and type I IFN-mediated suppression, a mechanism that can be overcome by prior immunity to reduce bacterial burdens.

The Gist

The Big Picture: A Broken Alarm System

Imagine your lungs are a bustling city under siege by an invisible enemy: Tuberculosis (TB). To fight this enemy, your body sends in a special police force called immune cells. These cells have a "command center" that receives orders from a general named Interferon-gamma (IFNγ).

The general's orders are simple: "Lock down the building, show your ID badges, and arrest the intruder!"

For a long time, scientists thought the problem with TB was that the body didn't send enough orders (not enough IFNγ). But this new study reveals a different, more frustrating problem: The orders are being sent, but some of the police officers can't hear them.

The Cast of Characters

Inside your lungs, there are different types of immune cells, like different units in a police department:

1. Alveolar Macrophages (AM): The "Veteran Officers." They live in the air sacs and are very good at following orders. When the General shouts, they immediately lock down and fight.
2. Monocyte-Derived Cells (MNC2): The "Rookie Officers." They are decent at following orders, though not quite as sharp as the veterans.
3. MNC1 (The "Permissive" Cells): The "Sleeping Officers." These are the new recruits that arrive during a chronic infection. They are the main hiding spot for the TB bacteria. The problem? They are deaf to the General's orders.

The Discovery: Why TB Hides in Plain Sight

The researchers discovered that the MNC1 cells have a broken radio. Even when the General (IFNγ) is screaming orders, these cells don't react.

• The Broken Radio: These cells have very few antennas (receptors) to catch the signal. Even if they catch a signal, their internal wiring (signaling proteins) is weak.
• The Result: Because they don't hear the orders, they don't lock down. They don't show their ID badges (MHC-II molecules), which means they can't call for backup (T-cells). They essentially become a safe house where the TB bacteria can live, eat, and multiply without being attacked.

The Interference: Static on the Line

Why are these cells so deaf? The study found a "jammer" interfering with the signal.

• Type I Interferon (The Jammer): This is another type of signal your body produces during infection. Usually, it helps fight viruses. But in the case of TB, it acts like static noise on the radio.
• The Effect: This static drowns out the General's orders specifically for the MNC1 cells. It tells them, "Don't show your ID badges," which prevents the T-cells from recognizing the infection.

The Twist: Training the Recruits

Here is the most exciting part of the study. The researchers found that this "broken radio" isn't a permanent defect. It's a habit that can be broken.

They used a model called CoMtb (Contained TB), which is like giving the immune system a training drill with a fake, harmless version of the enemy before the real attack.

• The Training Effect: When the body had this "prior immunity" (the training drill), the MNC1 cells changed. They grew new antennas and fixed their wiring.
• The Result: When the real TB attack happened later, these previously "deaf" cells could finally hear the General. They locked down, showed their ID badges, and successfully kicked the bacteria out. The bacterial load in the lungs dropped significantly.

The Takeaway: A New Strategy for Vaccines

This study changes how we think about fighting TB.

• Old Idea: We need to shout louder (make more IFNγ).
• New Idea: We need to fix the radios of the specific cells that are hiding the bacteria.

The researchers suggest that future vaccines or medicines shouldn't just try to boost the immune system generally. Instead, they should focus on reprogramming these specific "sleeping" cells (MNC1) so they can hear the alarm again.

In short: TB wins because it finds a specific type of immune cell that ignores the alarm. But if we can "train" those cells to listen, we can turn them from the bacteria's safe house into its worst nightmare.

Technical Summary

1. Problem Statement

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of death globally. A central paradox in TB immunology is that while Interferon-gamma (IFNγ) is essential for host defense, vaccines that primarily induce IFNγ often fail to provide robust protection, and increasing IFNγ levels alone does not always improve bacterial control.

Recent studies have established that lung mononuclear phagocytes (MNP) are heterogeneous during chronic infection. Specifically:

• Alveolar Macrophages (AM) effectively restrict Mtb.
• Monocyte-derived cells (MNCs) serve as the major bacterial reservoir.
• Within MNCs, the CD11c^lo subset (MNC1) is the most permissive to Mtb growth, while the CD11c^hi subset (MNC2) is intermediate.

The specific mechanisms driving this functional heterogeneity, particularly why MNC1 cells fail to respond to IFNγ signals compared to AM and MNC2, remain poorly defined. This study aims to elucidate the cell-intrinsic defects in IFNγ signaling within MNC1 and determine if these defects are reversible.

2. Methodology

The study employed a multi-faceted approach using murine models of TB infection:

• Mouse Models: C57BL/6 mice infected via aerosol with Mtb H37Rv (ZsGreen/mCherry tagged) to establish chronic infection (28 days post-infection, dpi).
• Cell Sorting & RNA-seq: Flow-sorted lung MNP subsets (AM, MNC1, MNC2) were analyzed using bulk RNA sequencing (GSE220147) to profile gene expression, specifically focusing on IFNγ-responsive genes and signaling pathways.
• Ex Vivo Stimulation: Lung single-cell suspensions were treated with recombinant IFNγ to assess immediate signaling responses (pSTAT1) via flow cytometry and immunofluorescence.
• Antigen Presentation Assays: Sorted MNP subsets were co-cultured with antigen-specific Th1 TCR-transgenic CD4 T cells (C7 or P25) in the presence of peptide antigens. T cell activation was measured via IFNγ ELISA.
• Type I IFN Manipulation:
  • In vitro: Bone marrow-derived macrophages (BMDM) from WT and Ifnar1^-/- mice were differentiated with IFNγ and/or IFNβ.
  • In vivo: Mixed bone marrow chimeric mice (WT + Ifnar1^-/-) were generated to assess the role of Type I IFN in regulating MHC-II expression in specific lung subsets during infection.
• Contained Mtb (CoMtb) Model: Mice were intradermally infected in the ear to establish contained infection without lung dissemination, followed by aerosol challenge. This model tests "trained immunity" and the effect of prior immunity on subsequent lung infection.
• Genetic Knockout Chimeras: Mixed bone marrow chimeras (WT + Ifngr1^-/-) were used to determine if IFNγ signaling is required for CoMtb-mediated protection in specific cell subsets.

3. Key Contributions & Results

A. MNC1 Cells Exhibit Defective IFNγ Signaling

• Transcriptional Deficit: RNA-seq analysis revealed that MNC1 cells express significantly lower levels of IFNγ-responsive genes compared to AM and MNC2.
• Signaling Machinery: MNC1 cells showed reduced mRNA and protein levels of key IFNγ pathway components, including IFNGR2, STAT1, and IRF1.
• Functional Response: Upon ex vivo IFNγ stimulation, MNC1 cells exhibited a blunted phosphorylation of STAT1 (pSTAT1) compared to AM and MNC2. This defect was observed at both the cytoplasmic and nuclear levels, indicating impaired signal transduction proximal to STAT1 activation.

B. Impaired Antigen Presentation

• MHC-II Downregulation: Due to poor IFNγ signaling, MNC1 cells expressed lower levels of MHC-II and its invariant chain CD74, as well as the master regulator CIITA.
• T Cell Activation Failure: Co-culture experiments demonstrated that MNC1 cells were significantly less efficient at presenting Mtb antigens to CD4 T cells compared to AM and MNC2, resulting in reduced T cell activation (IFNγ production).

C. Role of Type I IFN

• Mechanism of Suppression: MNC1 and MNC2 cells exhibited a higher "Type I IFN signature" than AM. The study demonstrated that Type I IFN (IFNβ) suppresses IFNγ-mediated upregulation of MHC-II.
• Validation: In Ifnar1^-/- BMDMs and chimeric mice, the inhibitory effect of Type I IFN on MHC-II expression was abolished. In vivo, deleting Ifnar1 in myeloid cells restored MHC-II expression in lung MNP subsets, confirming that Type I IFN signaling antagonizes IFNγ responses in Mtb infection.

D. Reversibility via Prior Immunity (CoMtb)

• Reprogramming: Mice with prior contained Mtb infection (CoMtb) showed improved IFNγ responsiveness in their bone marrow monocytes and subsequent lung MNC1/MNC2 cells upon aerosol challenge.
• Enhanced Markers: CoMtb mice exhibited increased pSTAT1, IFNGR2, MHC-II, and NOS2 levels in MNC1 and MNC2 cells.
• Improved Control: This enhanced responsiveness correlated with a significant reduction in Mtb burden (CFU) within MNC1 (2.7-fold decrease) and MNC2 cells.
• Dependency: The protective effect of CoMtb in monocyte-derived cells was dependent on IFNγ signaling, as Ifngr1^-/- myeloid cells in chimeric mice failed to control Mtb effectively, even in the presence of prior immunity. Notably, this effect was specific to monocyte-derived cells, as AMs showed minimal improvement in bacterial control via this mechanism in the chronic phase.

4. Significance and Conclusion

• Mechanistic Insight: The study identifies a specific "bottleneck" in TB immunity: the CD11c^lo monocyte-derived macrophage (MNC1) is intrinsically defective in IFNγ signaling due to low expression of signaling proteins and suppression by Type I IFN. This renders them a permissive niche for Mtb persistence.
• Paradox Resolution: It explains why high IFNγ production alone fails to clear TB; the target cells (MNC1) are unresponsive to the signal.
• Therapeutic Implications:
  • Host-Directed Therapy (HDT): Strategies that block Type I IFN signaling or directly boost IFNγ pathway components in MNC1 could enhance bacterial clearance.
  • Vaccine Design: Effective vaccines may need to induce "trained immunity" (similar to the CoMtb model) that reprograms monocyte precursors to overcome IFNγ hyporesponsiveness, rather than simply increasing cytokine production.
• Future Directions: The authors suggest that the link between IFNγ responsiveness and lysosome biogenesis (a previously identified defect in MNC1) may share a common developmental regulatory pathway, warranting further investigation.

In summary, the paper demonstrates that heterogeneous IFNγ responsiveness among lung macrophage subsets is a critical determinant of Mtb persistence and that this defect is reversible through prior immunity, offering a new target for TB therapeutics.